NATF is actively monitoring the situation around COVID-19. The health and safety of conference attendees and partners is our top priority. We will continue to assess the situation in the coming weeks and will communicate updates along the way by June 1. We remain dedicated to disseminating the most up-to-date science in CTEPH — weather in-person or virtually!
Earn up to 10.5 CME Credits!
The United States CTEPH Proceedings 2021 will provide a multidisciplinary framework for the evaluation and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). Covered topics will include:
- The epidemiology of chronic thromboembolic disease in the US
- Contemporary approaches to diagnosing CTEPH
- The latest in surgical advancements
- The role of pulmonary hypertension (PH) targeted medical therapy and balloon pulmonary angioplasty (BPA) in the management of inoperable CTEPH
The conference format will comprise didactic presentations, debates, and panel discussions involving national and international experts in the field. There will be scheduled opportunities throughout the symposium for interactive audience participation. Attendees will also be encouraged to submit and present scientific abstracts and unique clinical cases related to CTEPH and other large-vessel pulmonary vascular diseases.
This program has been designed to provide internists, pulmonologists, cardiologists, cardiovascular surgeons, interventional cardiologists and radiologists, anesthesiologists, thoracic radiologists, nurses, and allied healthcare professionals with state-of-the-art information to evaluate and manage patients with CTEPH.
- Discuss an updated understanding of the epidemiology and pathophysiology of CTEPH
- Describe the latest diagnostic modalities and evaluative approach to patients with suspected chronic thromboembolic disease
- Discuss the advancements in the surgical procedure, pulmonary thromboendarterectomy, currently available for patients with chronic thromboembolic disease and CTEPH
- Explain the role of balloon pulmonary angioplasty in the management of inoperable CTEPH
- Define the role of pulmonary hypertension targeted medical therapy in selected patient groups with CTEPH
- William R. Auger, MD
- Sonja Bartolome, MD (University of Texas, Southwestern)
- Todd Bull, MD (University of Colorado)
- Richard N. Channick, MD (University of California, Los Angeles)
- Michael Cuttica, MD (Northwestern University)
- Jack Haney, MD (Duke University)
- Gustavo Heresi, MD (Cleveland Clinic)
- Michael M. Madani, MD (University of California, San Diego)
- Vallerie McLaughlin, MD (University of Michigan)
- Ivan Robbins, MD (Vanderbilt University)
- Anjali Vaidya, MD (Temple University)
- Alison Witkin, MD (MGH, Harvard University)